Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.

The aim of this work was to synthesize Lys(1)(α,γ-Folate)-Lys(3)((177)Lu-DOTA)-Bombesin (1-14) ((177)Lu-Folate-BN), as well as to assess its potential for molecular imaging and targeted radiotherapy of breast tumors expressing folate receptors (FR) and gastrin-releasing peptide receptors (GRPR). Radiation absorbed doses of (177)Lu-Folate-BN (74 MBq, i.v.) estimated in athymic mice with T47D-induced breast tumors (positive to FR and GRPR), showed tumor doses of 23.9±2.1 Gy. T47D-tumors were clearly visible (Micro-SPECT/CT images). (177)Lu-Folate-BN demonstrated properties suitable as a theranostic radiopharmaceutical.

[1]  R. Jensen,et al.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status. , 2011, Current drug delivery.

[2]  J. Parry,et al.  MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide Receptor , 2006, Breast Cancer Research and Treatment.

[3]  Clara L Santos-Cuevas,et al.  Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with (177)Lu and Conjugated to Peptides. , 2015, Current radiopharmaceuticals.

[4]  Sujay Shah,et al.  Functional characterization and expression of folate receptor-α in T47D human breast cancer cells , 2015 .

[5]  D. O'Shannessy,et al.  Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease , 2012, SpringerPlus.

[6]  D. Hörsch,et al.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  G. de Vincentis,et al.  Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. , 2002, Cancer biotherapy & radiopharmaceuticals.

[8]  Jing Xie,et al.  Clinical translation of folate receptor-targeted therapeutics , 2012, Expert opinion on drug delivery.

[9]  Josefine Reber,et al.  177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy , 2013, Molecular Cancer Therapeutics.

[10]  L. Kelemen,et al.  The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander? , 2006, International journal of cancer.

[11]  M. R. A. Pillai,et al.  Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. , 2015, Chemical reviews.

[12]  Weiyue Lu,et al.  Isomeric folate-conjugated polymeric micelles bind to folate receptors and display anticancer effects. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[13]  J. Lehmann,et al.  Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. , 2005, Cancer biotherapy & radiopharmaceuticals.

[14]  R. Sadeghi,et al.  Diagnostic value of 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions , 2014, Nuclear medicine communications.

[15]  H. Wagner,et al.  Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. , 1998, Bioconjugate chemistry.

[16]  E. Morales-Ávila,et al.  177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing α(ν)β(3) integrins , 2012 .

[17]  C. Santos-Cuevas,et al.  Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women , 2008, Nuclear medicine communications.

[18]  Patrick Pauwels,et al.  Gastrin-Releasing Peptide Receptor Imaging in Human Breast Carcinoma Versus Immunohistochemistry , 2008, Journal of Nuclear Medicine.

[19]  Adelailson Peixoto,et al.  Computer-assisted coloring and illuminating based on a region-tree structure , 2012, SpringerPlus.

[20]  S. Ametamey,et al.  Radiosynthesis and preclinical evaluation of 3'-Aza-2'-[(18)F]fluorofolic acid: a novel PET radiotracer for folate receptor targeting. , 2013, Bioconjugate chemistry.

[21]  B. Wängler,et al.  Radiolabeled Heterobivalent Peptidic Ligands: an Approach with High Future Potential for in vivo Imaging and Therapy of Malignant Diseases , 2013, ChemMedChem.

[22]  Marion de Jong,et al.  In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer , 2015, The Journal of Nuclear Medicine.

[23]  D. Hicks,et al.  Folate receptor α associated with triple-negative breast cancer and poor prognosis. , 2014, Archives of pathology & laboratory medicine.

[24]  Samantha V. Sublett,et al.  In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. , 2009, Nuclear medicine and biology.